Savant Capital LLC Acquires 14,930 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Savant Capital LLC lifted its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 106.6% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 28,936 shares of the biotechnology company's stock after purchasing an additional 14,930 shares during the quarter. Savant Capital LLC's holdings in BioMarin Pharmaceutical were worth $1,902,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. Stoneridge Investment Partners LLC boosted its stake in BioMarin Pharmaceutical by 151.7% during the 4th quarter. Stoneridge Investment Partners LLC now owns 10,545 shares of the biotechnology company's stock valued at $693,000 after purchasing an additional 6,355 shares during the last quarter. WCM Investment Management LLC boosted its position in shares of BioMarin Pharmaceutical by 3.5% during the fourth quarter. WCM Investment Management LLC now owns 17,540 shares of the biotechnology company's stock valued at $1,148,000 after buying an additional 595 shares during the last quarter. Entropy Technologies LP purchased a new position in shares of BioMarin Pharmaceutical during the fourth quarter valued at approximately $500,000. Empowered Funds LLC purchased a new stake in BioMarin Pharmaceutical in the 4th quarter valued at $257,000. Finally, Advisors Preferred LLC purchased a new stake in BioMarin Pharmaceutical in the 4th quarter valued at $953,000. 98.71% of the stock is currently owned by institutional investors.

BioMarin Pharmaceutical Stock Performance

Shares of NASDAQ:BMRN traded up $0.43 during trading on Monday, hitting $64.85. 1,048,855 shares of the company were exchanged, compared to its average volume of 1,674,690. The company has a market cap of $12.36 billion, a PE ratio of 38.83, a P/E/G ratio of 0.57 and a beta of 0.28. BioMarin Pharmaceutical Inc. has a 52-week low of $60.63 and a 52-week high of $94.85. The company has a debt-to-equity ratio of 0.11, a current ratio of 4.27 and a quick ratio of 2.62. The stock has a 50 day moving average of $64.86 and a 200 day moving average of $71.38.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on BMRN shares. JPMorgan Chase & Co. reduced their target price on shares of BioMarin Pharmaceutical from $110.00 to $109.00 and set an "overweight" rating for the company in a research note on Wednesday, October 30th. UBS Group increased their price objective on shares of BioMarin Pharmaceutical from $104.00 to $106.00 and gave the company a "buy" rating in a research note on Wednesday, October 30th. Royal Bank of Canada reissued a "sector perform" rating and set a $80.00 target price on shares of BioMarin Pharmaceutical in a research report on Wednesday, October 30th. William Blair lowered BioMarin Pharmaceutical from an "outperform" rating to a "market perform" rating in a report on Wednesday, October 30th. Finally, Robert W. Baird dropped their price target on BioMarin Pharmaceutical from $72.00 to $65.00 and set a "neutral" rating on the stock in a report on Wednesday, October 30th. Seven equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat, BioMarin Pharmaceutical has a consensus rating of "Moderate Buy" and a consensus price target of $94.20.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.